methimazole has been researched along with Osteoporosis--Postmenopausal* in 2 studies
2 other study(ies) available for methimazole and Osteoporosis--Postmenopausal
| Article | Year |
|---|---|
[A case of Plummer disease that appeared in older old age after 10-year course of subclinical hyperthyroidism].
A 81-year-old woman with a thyroid tumor and subclinical hyperthyroidism since ten years ago was admitted to our hospital for palpitations and hyperthyroidism (FT(4) 1.75 ng/dl, FT(3) 5.37 pg/ml, TSH<0.03 microIU/ml). Although thyroid stimulating antibody (TSAb) was transiently and mildly positive, anti-TSH receptor antibody (TRAb), microsome test, and thyroid test were negative. Thyroid echogram showed an isoechoic nodule in the left lobe (33 x 42 x 22 mm) and a small nodule (10 x 15 x 9 mm) in right lobe. Thyroid scintiscan showed a hyperfunctional (hot) nodule in left thyroid lobe with suppressed uptake in the remainder of the gland. The uptake rate of thyroidal radioiodine ((123)I) in 24 hours was within the normal range (7.3%). Based on the above findings, a diagnosis of Plummer disease was made. Since she refused invasive surgical or radioiodine treatment, she was treated with 10 mg thiamazole daily. After treatment with propranolol and thiamazole, the thyrotoxic symptoms disappeared and thyroid function returned to normal level. She had osteoporosis but she had neither atrial fibrillation nor cardiac symptoms. This was a rare case of Plummer disease that appeared in extremely old age after a long course of subclinical hyperthyroidism. Topics: Adenoma; Aged, 80 and over; Antithyroid Agents; Autoantibodies; Female; Humans; Hyperthyroidism; Methimazole; Osteoporosis, Postmenopausal; Thyroid Nodule; Thyrotropin | 2007 |
Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole.
High levels of thyroid hormones accelerate bone turnover. The aim of the present study was to evaluate the effects of treatment with alendronate in patients affected by hyperthyroidism and osteoporosis. We studied 40 hyperthyroid patients with bone loss, divided into two groups according to menopausal state. Before treatment and after 6 and 12 months, serum thyroid hormones levels, serum osteocalcin level and bone mineral density were evaluated. In all patients we observed an increase in bone mineral density after treatment with alendronate, and a corresponding decrease in serum osteocalcin level. Topics: Adult; Alendronate; Bone Density; Female; Humans; Hyperthyroidism; Methimazole; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Thyrotropin; Thyroxine; Triiodothyronine | 1996 |